Pubblicazioni

Autori:

Gajofatto, Alberto; Turatti, Marco

Titolo:

Investigational immunosuppressants in early stage clinical trials for the treatment of multiple sclerosis

Anno:

2018

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

A Stampa

Referee:

Sì

Nome rivista:

Expert Opinion on Investigational Drugs

ISSN Rivista:

1354-3784

N° Volume:

27

Numero o Fascicolo:

3

Intervallo pagine:

273-286

Parole chiave:

B-cell therapy; clinical trial; experimental drug; immunosuppressant; monoclonal antibody; multiple sclerosis; sphingosine 1-phosphate modulator

Breve descrizione dei contenuti:

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with an immune mediated pathogenesis. Several therapies that suppress or modulate diverse immune system functions have been used for decades with the aim of modifying the disease course. However, these treatments have either limited efficacy or potentially serious adverse events that prevent first-line use on large scale. Areas covered. The aim of the present article is to review ongoing or recently completed clinical trials investigating immunosuppressive drugs for MS. The websites clinicaltrials.gov, clinicaltrialsregister.eu, and pubmed.gov were searched for phase 1, phase 2, and phase 3 trials starting from 2012. Twelve drugs were identified, including 7 monoclonal antibodies and 5 small molecules. Expert opinion. Current or recently completed trials of immunosuppressants for MS are mainly proof-of-concept studies enrolling patients with relapsing disease and using efficacy endpoints based on magnetic resonance imaging measures of inflammatory activity. Sphingosine 1-phosphate receptor modulators and B-cell depleting therapies represent the most commonly investigated drugs, suggesting that mechanisms of action that have already shown promise for MS treatment are being exploited to find new therapies with improved safety, tolerability, and convenience of dosing. Clinical trials of immunosuppressants for progressive MS are largely lacking.

Pagina Web:

https://doi.org/10.1080/13543784.2018.1442437

Id prodotto:

101649

Handle IRIS:

11562/976192

ultima modifica:

26 novembre 2022

Citazione bibliografica:

Gajofatto, Alberto; Turatti, Marco, Investigational immunosuppressants in early stage clinical trials for the treatment of multiple sclerosis «Expert Opinion on Investigational Drugs» , vol. 27 , n. 3 , 2018 , pp. 273-286

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo